The company is mainly engaged in the development of ethical drug business, consumer healthcare business and other business. In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries, manufacturing and selling pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark.
Cyborg Score Rationale
Zeria demonstrates solid fundamentals as a established mid-cap pharmaceutical player with strong positioning in gastroenterology and meaningful international presence through subsidiaries. Revenue growth of 15.3% YoY and net income growth of 28.5% indicate operational momentum, though modest analyst coverage suggests limited institutional attention.
Top Insights
Leading position in Japanese gastroenterology pharmaceutical market with specialized product portfolio
International expansion through acquisitions: Acquired Tillotts Pharma AG (Switzerland) in 2009 with operations across 10+ countries
Strong recent financial performance: 15.3% revenue growth to $604.2M and 28.5% net income growth in 2025
Diversified business model spanning ethical drugs, consumer healthcare, and complementary products (cosmetics, food additives, medical devices)
Named Competitors
Ethical Pharmaceuticals & Consumer Healthcare Products — Major Japanese pharmaceutical competitor